Teleflex Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
TeleflexDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -36.2% zurückgegangen, während in der Branche Medical Equipment die Gewinne wachsen. Die Umsatzerlöse sind rückläufig mit einer durchschnittlichen Rate von 9.1% pro Jahr. Teleflex Die Eigenkapitalrendite des Unternehmens beträgt 0.04%, und die Nettomargen liegen bei 0.06%.
Wichtige Informationen
-36.17%
Wachstumsrate der Gewinne
-36.25%
EPS-Wachstumsrate
| Medical Equipment Wachstum der Industrie | 8.90% |
| Wachstumsrate der Einnahmen | -9.13% |
| Eigenkapitalrendite | 0.044% |
| Netto-Marge | 0.064% |
| Letzte Ertragsaktualisierung | 31 Mar 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Narrativ-Update • Jun 22
TFX: Biotronik Synergies And Activist Pressure Will Shape Execution Risk Going Forward
Analysts have raised the fair value estimate for Teleflex stock from $116.81 to $135.00, reflecting updated assumptions around capital deployment, Biotronik-related synergies, potential activist-driven value creation, and a slightly higher future P/E multiple. Analyst Commentary Recent Street research on Teleflex has focused on how potential Biotronik synergies, capital deployment plans, and possible activist involvement could influence the stock's risk and reward profile.Analyseartikel • Jun 19
Teleflex (TFX) Stock Could Be 11.6% Undervalued After Q1 Revenue Beat
Teleflex stock reaction centered on earnings, not new debt issue Teleflex (TFX) has been drawing attention after Q1 revenue topped analyst expectations and investors responded positively, even as the company issued new senior notes and reiterated full year EPS guidance below prior estimates. The recent share price move appears more closely linked to Teleflex's earnings update, where revenue performance and progress on its transformation plan supported sentiment, rather than to the sizeable...
Narrativ-Update • Jun 06
TFX: Portfolio Reset And Recent Upgrades Will Shape Balanced Forward Outlook
Analysts have raised their fair value estimate for Teleflex from $129.25 to about $143.67, citing a lower required discount rate, an updated view on revenue growth and margins, and a higher assumed future P/E multiple following several recent upgrades and target increases from major firms. Analyst Commentary Recent Street research on Teleflex has leaned constructive, with several firms updating ratings and price targets in quick succession.
Narrativ-Update • May 23
TFX: Business Separation And Portfolio Shift Will Drive Future Earnings Repricing
Narrative Update on Teleflex The updated analyst price target for Teleflex moves to $155 from $147, with analysts citing recent upgrades and price target increases, along with the company's ongoing business separation and portfolio optimization efforts, as key supports for the higher fair value and slightly adjusted discount rate and P/E assumptions. Analyst Commentary Recent street research around Teleflex has leaned positive, with several bullish analysts updating views in quick succession.Narrativ-Update • May 02
TFX: Business Separation And Portfolio Focus Will Reshape Future Earnings Profile
Analysts have reduced their fair value estimate for Teleflex to $147 from $155, citing updated assumptions for revenue growth, profit margins, and future P/E multiples following recent upgrades and price target increases from several research firms. Analyst Commentary Recent research has skewed more optimistic on Teleflex, with several bullish analysts updating their views following the company’s Q4 results, guidance, and plans for a major business transformation.Narrativ-Update • Apr 17
TFX: Business Separation Execution And Activist Pressure Will Constrain Forward Upside
Teleflex's analyst price target is now framed slightly higher, moving from about $115 to roughly $117. Analysts are factoring in updated assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E following recent upgrades and price target increases tied to the company's ongoing business separation and portfolio optimization efforts.Narrativ-Update • Apr 03
TFX: Business Separation And Activist Pressure Will Shape Balanced Forward Outlook
Analysts have raised their average price target for Teleflex to $125 from $115. They cite the company’s ongoing business separation, portfolio optimization, and preparation for future value-creating opportunities as key reasons for the change.Narrativ-Update • Mar 20
TFX: Business Separation And Leadership Changes Will Shape Balanced Forward Outlook
Narrative update Analysts have raised the Teleflex price target by $10, to $125 from $115, citing the company's business separation efforts, portfolio optimization, and positioning for future value creating opportunities following recent results and guidance. Analyst Commentary Recent research highlights a mixed backdrop for Teleflex, with some firms adjusting targets higher while others stay guarded.Narrativ-Update • Mar 06
TFX: Business Separation And Portfolio Optimization Will Drive Future Earnings Quality
Narrative Update on Teleflex The analyst price target on Teleflex has shifted toward $125, with analysts pointing to the company’s ongoing business separation, portfolio optimization, and positioning for future value-creating opportunities as key factors behind the revised outlook. Analyst Commentary Bullish analysts are pointing to recent price target moves and rating actions as signals of growing confidence in Teleflex’s ability to execute on its transformation plan and to support higher valuation levels over time.Narrativ-Update • Feb 20
TFX: Higher Margin Assumptions And CEO Transition Will Shape Bullish Outlook
Narrative Update on Teleflex The updated analyst price target on Teleflex has shifted by $23, with analysts citing refreshed views on long term profit margins and a slightly higher assumed future P/E multiple as key drivers behind the change. Analyst Commentary Recent Street research on Teleflex reflects a mix of optimism about the company’s long term potential and caution around valuation and execution, which helps explain the updated price target.Narrativ-Update • Feb 06
TFX: CEO Transition And Refined Assumptions Will Shape Bullish Future Outlook
Analysts have adjusted their price targets on Teleflex by aligning fair value estimates to about $129.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions highlighted in recent research, including a Wells Fargo target cut and a Needham upgrade.Narrativ-Update • Jan 23
TFX: Leadership Transition And Softer Demand Will Shape Steady Forward Outlook
Analysts kept their Teleflex fair value estimate steady at US$115.00, as slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E led them to view the prior price target as still appropriate. What's in the News Board member Stuart Randle has been appointed Interim President and CEO effective January 8, 2026, replacing Liam Kelly.Narrativ-Update • Jan 09
TFX: Softer Demand And Leadership Change Will Shape Balanced Outlook
Analysts have reduced their price target on Teleflex from US$120.00 to US$115.00, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News Teleflex issued preliminary 2025 revenue guidance of US$3.270b to US$3.278b, below its prior outlook of US$3.305b to US$3.320b, citing softer demand for intra aortic balloon pumps and catheters in the U.S. and Asia, delays in OEM purchase orders, and lower order volumes across parts of its portfolio (Key Developments).Narrativ-Update • Dec 20
TFX: Margin Expansion Will Drive Stronger Earnings Despite Revenue Headwinds
Analysts have raised their price target on Teleflex from 152.80 dollars to 155.00 dollars, reflecting expectations for meaningfully higher profit margins that more than offset slightly slower projected revenue growth and a lower future earnings multiple. What's in the News Teleflex narrowed its full year 2025 GAAP revenue growth outlook to 9.10% to 9.60%, and now expects revenue between 3,325 million dollars and 3,340 million dollars.Seeking Alpha • Dec 10
Teleflex: Selling, But How Much?
Summary Teleflex Incorporated rebounded from lows after announcing a $2.03B divestiture of Acute Care, Interventional Urology, and OEM businesses. TFX will use $1B of net proceeds for share buybacks, reducing pro forma net debt to $1.5B, but revenue impact remains ambiguous. Shares now trade at 10x adjusted earnings, with market reaction positive despite uncertainty around divested revenue figures. I maintain a cautious long position, closely monitoring Q4 results to clarify divestment implications and future margin trajectory. Read the full article on Seeking AlphaNarrativ-Update • Dec 06
TFX: Diabetes Trial And Goodwill Charge Will Shape Balanced Future Outlook
Analysts have modestly adjusted their price target on Teleflex, keeping fair value steady at approximately $124.14 per share while refining assumptions for a slightly lower discount rate and marginally improved long term valuation metrics. This reflects incremental confidence in the company’s earnings durability.Narrativ-Update • Nov 22
TFX: Future Diabetes Trial Progress Will Drive Upside Despite Margin Pressures
Teleflex's analyst price target has been revised downward by $3.57 to $124.14. Analysts cite modest reductions in expected profit margins and growth as driving factors for the update.Analyseartikel • Nov 09
Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34
Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...Narrativ-Update • Nov 07
TFX: Future Advances In Diabetes Trials And Asian Market Expansion Will Drive Upside
Analysts have revised their price target for Teleflex downward from $132.63 to $127.71. They cite higher discount rates and softer revenue growth projections, despite improved profit margins and a lower expected future price-to-earnings ratio.Analyseartikel • Oct 30
Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing
Teleflex Incorporated's ( NYSE:TFX ) price-to-earnings (or "P/E") ratio of 29.5x might make it look like a strong sell...Analyseartikel • Sep 11
These 4 Measures Indicate That Teleflex (NYSE:TFX) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narrativ-Update • Aug 29
Acquisitions And Asian Expansion Will Broaden Healthcare Horizons
Despite a near-term upside from strong Q2 results, Teleflex’s consensus price target has been revised down to $132.62 due to persistently modest organic growth and muted EPS increases, with valuation already reflecting current expectations despite anticipated second-half acceleration. Analyst Commentary Strong Q2 results provided near-term upside surprise.Analyseartikel • Aug 04
Results: Teleflex Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates
Last week saw the newest quarterly earnings release from Teleflex Incorporated ( NYSE:TFX ), an important milestone in...Analyseartikel • Aug 03
Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34
Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...Analyseartikel • Jul 10
Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 35.1x Teleflex Incorporated ( NYSE:TFX ) may be sending very bearish...Seeking Alpha • Mar 02
Teleflex's Bold Transformation: Why I'm Skeptical On Value Creation
Summary Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak revenue growth and margin leverage, with potential risks from tariffs and poor execution in key areas. The acquisition of BIOTRONIK's vascular intervention business is risky; it expands Teleflex's vascular intervention business, but the end markets aren't growing that fast and the company is a smaller player. Splitting the business into RemainCo and NewCo makes strategic sense, but NewCo may struggle with growth and margin leverage as a smaller entity. Even with conservative modeling and valuation assumptions, Teleflex stock looks undervalued by more than 20%, but it's tough to recommend a stock where I have serious doubts about execution and strategy. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Teleflex Incorporated: Compelling Only On One Metric
Summary Teleflex Incorporated, a diversified medical device company, saw a 17% stock drop after Q3 results in late October. The stock now trades at under 13.5 EPS (non-GAAP) and at the equity's lowest price-to-sales ratio in a decade. Have the shares fallen into the 'buy zone'? An analysis of Teleflex Incorporated follows in the paragraphs below. Read the full article on Seeking AlphaAufschlüsselung der Einnahmen und Ausgaben
Aufschlüsselung der Einnahmen und Ausgaben
Wie Teleflex Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 26 | 2,127 | 1 | 753 | 164 |
| 31 Dec 25 | 1,993 | 59 | 687 | 145 |
| 28 Sep 25 | 1,556 | -384 | 570 | 113 |
| 29 Jun 25 | 1,407 | 136 | 528 | 94 |
| 30 Mar 25 | 1,376 | 94 | 569 | 97 |
| 31 Dec 24 | 1,700 | 57 | 797 | 109 |
| 29 Sep 24 | 3,026 | 238 | 1,175 | 153 |
| 30 Jun 24 | 3,008 | 265 | 1,165 | 152 |
| 31 Mar 24 | 3,001 | 296 | 1,153 | 150 |
| 31 Dec 23 | 1,712 | 144 | 695 | 114 |
| 01 Oct 23 | 2,959 | 405 | 925 | 161 |
| 02 Jul 23 | 2,899 | 369 | 904 | 161 |
| 02 Apr 23 | 2,860 | 363 | 888 | 159 |
| 31 Dec 22 | 2,791 | 363 | 861 | 154 |
| 25 Sep 22 | 2,795 | 412 | 862 | 147 |
| 26 Jun 22 | 2,808 | 510 | 856 | 141 |
| 27 Mar 22 | 2,817 | 488 | 859 | 137 |
| 31 Dec 21 | 2,810 | 485 | 852 | 131 |
| 26 Sep 21 | 2,759 | 434 | 836 | 129 |
| 27 Jun 21 | 2,687 | 351 | 829 | 126 |
| 28 Mar 21 | 2,540 | 280 | 784 | 122 |
| 31 Dec 20 | 2,537 | 336 | 782 | 120 |
| 27 Sep 20 | 2,507 | 367 | 772 | 117 |
| 28 Jun 20 | 2,527 | 479 | 770 | 116 |
| 29 Mar 20 | 2,612 | 551 | 798 | 114 |
| 31 Dec 19 | 2,595 | 462 | 798 | 114 |
| 29 Sep 19 | 2,556 | 442 | 804 | 111 |
| 30 Jun 19 | 2,517 | 269 | 812 | 109 |
| 31 Mar 19 | 2,475 | 183 | 814 | 107 |
| 31 Dec 18 | 2,448 | 196 | 744 | 106 |
| 30 Sep 18 | 2,402 | 66 | 822 | 104 |
| 01 Jul 18 | 2,327 | 89 | 784 | 99 |
| 01 Apr 18 | 2,246 | 170 | 738 | 93 |
| 31 Dec 17 | 2,146 | 155 | 696 | 85 |
| 01 Oct 17 | 2,065 | 259 | 634 | 75 |
| 02 Jul 17 | 1,986 | 246 | 611 | 69 |
| 02 Apr 17 | 1,931 | 227 | 594 | 64 |
| 31 Dec 16 | 1,868 | 237 | 570 | 59 |
| 25 Sep 16 | 1,828 | 267 | 569 | 56 |
| 26 Jun 16 | 1,816 | 262 | 569 | 54 |
| 27 Mar 16 | 1,795 | 248 | 568 | 52 |
| 31 Dec 15 | 1,799 | 236 | 574 | 52 |
| 27 Sep 15 | 1,798 | 197 | 578 | 56 |
Qualität der Erträge: TFX hat einen großen einmalig Verlust von $197.3M verbucht, der sich auf die Finanzergebnisse der letzten 12 Monate bis zum 31st March, 2026 auswirkt.
Wachsende Gewinnspanne: TFXDie aktuellen Gewinnspannen (0.06%) sind niedriger als im letzten Jahr (6.8%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: TFXDie Erträge des Unternehmens sind in den letzten 5 Jahren um 36.2% pro Jahr zurückgegangen.
Beschleunigtes Wachstum: TFXDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.
Erträge im Vergleich zur Industrie: TFX hatte im vergangenen Jahr ein negatives Gewinnwachstum (-98.6%), was einen Vergleich mit dem Branchendurchschnitt Medical Equipment (14.8%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: TFXDie Eigenkapitalrendite des Unternehmens (0.04%) wird als niedrig angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/02 12:42 |
| Aktienkurs zum Tagesende | 2026/07/02 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Teleflex Incorporated wird von 25 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Matthew Taylor | Barclays |
| Travis Steed | BofA Global Research |
| James Lucas | Brean Capital Historical (Janney Montgomery) |